H.C. Wainwright upgraded Sarepta (SRPT) to Neutral from Sell with an unchanged price target of $75. The firm cites the stock’s current ...
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was downgraded by stock analysts at Royal Bank of Canada from an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback